Wakefield Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Wakefield Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-53,081	Closed	-$1.67M	–	220
2026 Q2	$1.67M	Buy	53,081 +946	+2%	+$27.9K	0.38%	74
2026 Q1	$1.29M	Buy	52,135 +599	+1%	+$14.3K	0.34%	81
2025 Q4	$1.2M	Buy	+51,536	New	+$1.15M	0.33%	95

Other funds holding CPRX

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Wakefield Asset Management's CPRX Position: Q3 2026 in Review

Wakefield Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 53,081 shares — an estimated $1.67M sold.

Wakefield Asset Management first reported a position in CPRX in Q4 2025 and held it in 3 quarters. The position peaked at $1.67M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Wakefield Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Wakefield Asset Management sold 53,081 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.67M.
Wakefield Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and held it in 3 quarters.
Wakefield Asset Management's Catalyst Pharmaceutical position peaked at $1.67M in Q2 2026.
2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Wakefield Asset Management's 13F filing for Q3 2026, filed 5 Nov 2026.